top of page

Our History

In the fast-growing metroplex of Phoenix, Arizona, we formed Calviri in 2017 to end cancer. We were convinced this could be done because we had discovered a previously unappreciated, yet fundamental, molecular characteristic of all tumors that distinguishes them from healthy host cells. We had also invented chip technologies that would let us leverage our discovery to uniquely battle cancer.

 

After years of research and many patents, we are now developing multi-cancer tests to accurately detect stage 1 disease, which can be treated with our early-stage therapeutic vaccines. Our research has also shown us the path to the seeming impossible: a preventative cancer vaccine. All rooted in the power of our molecular discoveries and semiconductor inventions, we are now ready to globally provide diagnostics and vaccines that will end cancer.

Full stop.

Company Timeline

2017

2018

2019

2020

2021

2022

2023

2024

Company launches

​

Round 1 investor funding, $2.25MM

​

Stephen Johnston inducted into the National Academy of Inventors

Company obtains exclusive license to Johnston patents from ASU

​​​​

Open Philanthropy grant is funded, $6.4MM

Company initiates VACCS Trial

Independent Safety Board reports no adverse events in trial

​

New Board of Directors is formed

​

Round 2 investor funding, $5MM

Lab and production teams move to new sites in Phoenix and Tempe​

​

Company awarded Most Fundable Company title​

Scientific Advisory Board is formed​

​

VACCS trial enrollment of 800+ dogs completed

​

Round 3 investor funding, $11.3MM

Company moves to new Phoenix lab​

​

Open house celebration for new lab​

​

Company’s first scientific publication

​

Company’s first VACCS publication

VACCS trial completed â€‹â€‹

​

Company earns Arizona Bioscience Company of the Year Award 

​

Hemangiosarcoma (HSA) trial initiated

Our Board of Directors

Integrity. Responsibility. Dedication. 

Our Board of Directors is a team of successful leaders with diverse expertise, talents and backgrounds, yet all focused on equipping the company with the leadership tools to end cancer. 

Le Benger MD, Jeffrey (BOD)-Headshot 2023.jpg

Chairman, Director

Jeffrey Le Benger, MD, FACS

  • LinkedIn
Johnston, Stephen-Desert.png

Director, Co-Founder,

Calviri CEO

Stephen Albert Johnston

  • LinkedIn
Sykes, Kathryn (BOD)-Headshot.jpg

Director, Co-Founder,

Calviri VP Research & Product Development

Kathryn Sykes, PhD

  • LinkedIn
Screenshot 2024-06-27 at 2.27.08 PM.png

Director

Jacque Sokolov, MD

  • LinkedIn
McCallister, Michael-Headshot (Director).jpg

Director

Michael McCallister

  • LinkedIn

Calviri At A Glance:

Diagnostic Pipeline

  • Canine multi-cancer early detection test 

​

  • Human stage 1 breast cancer early detection 

​

  • Human predictive diagnostic test for response to checkpoint inhibitors

​

  • Human multi-cancer early detection test 

Vaccine Pipeline

  • Canine preventative cancer vaccine  

​

  • Canine stage 1 hemangiosarcoma (HSA) therapeutic vaccine 

​

  • Canine multi-cancer therapeutic vaccine 

Canine Trials

  • VACCS preventative vaccine trial completed 

​

  • HSA therapeutic vaccine trial initiated 

​

  • New preventative vaccine trial in development 

Human Trials

  • Renal medullary cancer (RMC) therapeutic vaccine trial in development  

​

  • NF-1 pediatric cancer therapeutic trial in development

Our Scientific Advisory Board

Expertise. Commitment. Motivation. 

Our Scientific Advisory Board is a team of intellectually rich scientists that steer Calviri’s innovations into world changing products. 

McInnis, Terry (SAB)-Headshot 2023 (Beig

Chairman

Terry A. McInnis, MD, MBA, MPH

  • LinkedIn
Johnston, Stephen-Desert.png

Calviri CEO

Stephen Albert Johnston

  • LinkedIn
Sykes, Kathryn (BOD)-Headshot.jpg

Calviri VP Research & Product Development

Kathryn Sykes PhD

  • LinkedIn
Lapidus, Stan (SAB)-Headshot 2023 (Bow Tie Hi Res for Cropped-Website).JPG

Scientific Advisor

Stan Lapidus

  • LinkedIn
Ballantyne, John Headshot (SAB)_edited.j

Scientific Advisor

John Ballantyne, PhD

  • LinkedIn
Lee MD, Peter P. (SAB)-Headshot 2023.jpg

Scientific Advisor

Peter P. Lee MD

  • LinkedIn
Dow, Steven Headshot (SAB).jpeg

Scientific Advisor

Steven W. Dow, DVM, PhD

  • LinkedIn

Literature & Media

Partners

Week of May 13th Graphic 1 (3)_edited.jp
Week of May 13th Graphic 1 (2)_edited.jp
Week of May 13th Graphic 1 (5)_edited.jp
Week of May 13th Graphic 1 (4)_edited.jp
Week of May 13th Graphic 1_edited.jpg
flint.png

Contact Us

Please direct any questions or comments you have for us via our contact form below.

Wexford-50-phoenix-Project-Hero-Image-PBC-1.jpg

850 N. 5th Street Phoenix, AZ

Thanks for submitting!

bottom of page